Neoadjuvant relatlimab and nivolumab in resectable melanoma

Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced melanoma 1 . We investigated this regimen in patients with resectable clinical stage III or oligometastatic stage IV melanoma (NCT02519322). Patient...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature (London) Ročník 611; číslo 7934; s. 155 - 160
Hlavní autori:	Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tetzlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, Tawbi, Hussein A.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 03.11.2022 Nature Publishing Group
Predmet:	631/67/1059/2325 631/67/1813/1634 Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Cancer therapies Clinical trials Drug Therapy, Combination Humanities and Social Sciences Humans Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immune system Immunotherapy Macrophages Macrophages - drug effects Melanoma Melanoma - drug therapy Melanoma - pathology Melanoma - surgery Metastases Metastasis Monoclonal antibodies multidisciplinary Myocarditis Neoadjuvant Therapy - adverse effects Neoadjuvant Therapy - methods Neoplasm Staging Nivolumab - adverse effects Nivolumab - therapeutic use Patients Relativity Response rates Safety Science Science (multidisciplinary) Solid tumors Surgery Survival Survival Rate Targeted cancer therapy Tumors
ISSN:	0028-0836, 1476-4687, 1476-4687
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!